

## COPY OF PAPERS ORIGINALLY FILED

PATENT

Docket No.: 19603/4071 (CRF-D-2598A)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Vivian E. Mack Strong et al.

Examiner:

Serial No.

09/782,936

B. Puri

Filed

February 14, 2001

Art Unit: 1633

For

USE OF COX-2 INHIBITORS TO TREAT

)

SEPSIS, COMPLICATIONS THEREOF, AND EP RECEPTOR MODULATION

RECEIVED

MAR - 6 2002

TRANSMITTAL LETTER

**TECH CENTER 1600/2900** 

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Transmitted herewith in the above-identified application are:

[X] Response to Restriction Requirement (1 page); and

[X] A self-addressed, prepaid postcard acknowledging receipt.

[X] The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. <u>14-1138</u>.

A duplicate copy of this sheet is enclosed.

Date: February 7, 2002

Ann R. Pokalsky

Registration No. 34,697

NIXON PEABODY LLP

Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051

Telephone: (716) 263-1304 Facsimile: (716) 263-1600

ARP/mm

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231,

on the date below.

メナルノ

Maria Matoe



## COPY OF PAPERS ORIGINALLY FILED

#61802 313102

PATENT

Docket No.: 19603/4071 (CRF-D-2598A)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Vivian E. Mack Strong et al.

Serial No. : 09/782,936

Filed : February 14, 2001

For : USE OF COX-2 INHIBITORS TO TREAT SEPSIS, COMPLICATIONS THEREOF, AND EP RECEPTOR MODULATION

MAR - 6 2002

TECH CENTER 1600/c

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the January 16, 2002, written restriction requirement, Applicants hereby elect Group I (i.e., claims 1, 2, 9, 12 and 15) with traverse for continued prosecution in the above-identified application.

Applicants submit that all groups of invention identified in the outstanding office action are closely related and, therefore, would require common areas of search and consideration. Thus, no benefit is derived from maintaining a restriction requirement and withdrawal of the restriction requirement is respectfully requested.

Date: February 7, 2002

NIXON PEABODY LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051 Telephone: (716) 263-1304

Facsimile: (716) 263-1600

ARP/mm

Respectfully submitted,

Ann R. Pokalasky

Registration No. 34,697

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mell in an envelope addressed to: Commissions for Patents, Weshington, D.C. 20231,

on the date below. 2/7/0 スレ

Maria Matos